Vanta Bioscience Ltd
Incorporated in 2016, Vanta Bioscience
Ltd is in the business of Preclinical Activities.[1]
- Market Cap ₹ 27.2 Cr.
- Current Price ₹ 43.1
- High / Low ₹ 102 / 37.0
- Stock P/E
- Book Value ₹ 21.6
- Dividend Yield 0.00 %
- ROCE -4.16 %
- ROE -14.2 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -4.25% over past five years.
- Company has a low return on equity of -14.3% over last 3 years.
- Debtor days have increased from 94.8 to 118 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
12.08 | 13.75 | 9.82 | 9.40 | 5.83 | 9.72 | 4.58 | |
8.81 | 9.38 | 5.87 | 5.93 | 8.22 | 8.41 | 5.72 | |
Operating Profit | 3.27 | 4.37 | 3.95 | 3.47 | -2.39 | 1.31 | -1.14 |
OPM % | 27.07% | 31.78% | 40.22% | 36.91% | -40.99% | 13.48% | -24.89% |
0.23 | 0.11 | 0.03 | 0.42 | 0.69 | 0.11 | 0.12 | |
Interest | 1.69 | 1.95 | 2.14 | 2.35 | 5.89 | 5.75 | 5.04 |
Depreciation | 0.71 | 1.19 | 1.25 | 1.32 | 2.67 | 4.50 | 4.64 |
Profit before tax | 1.10 | 1.34 | 0.59 | 0.22 | -10.26 | -8.83 | -10.70 |
Tax % | 36.36% | 24.63% | 23.73% | 40.91% | 1.75% | -2.49% | |
0.70 | 1.01 | 0.45 | 0.14 | -10.44 | -8.61 | -3.85 | |
EPS in Rs | 1.11 | 1.58 | 0.71 | 0.14 | -10.27 | -3.68 | -6.10 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -4% |
3 Years: | 0% |
TTM: | -52% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 14% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -21% |
3 Years: | -26% |
1 Year: | -20% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -7% |
3 Years: | -14% |
Last Year: | -14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 |
Reserves | 15.94 | 17.16 | 17.61 | 17.70 | 11.20 | 8.89 | 7.32 |
13.25 | 17.37 | 35.97 | 44.86 | 57.16 | 60.95 | 65.82 | |
3.51 | 7.74 | 9.74 | 12.53 | 10.04 | 9.25 | 6.20 | |
Total Liabilities | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.65 |
17.90 | 20.76 | 29.39 | 36.12 | 57.22 | 54.15 | 66.63 | |
CWIP | 3.70 | 7.00 | 19.34 | 28.47 | 10.60 | 12.53 | 0.00 |
Investments | 1.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
15.46 | 20.82 | 20.90 | 16.81 | 16.89 | 18.72 | 19.02 | |
Total Assets | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.65 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
-1.04 | 2.34 | 6.97 | 5.28 | -0.63 | 2.68 | |
-5.73 | -7.59 | -22.30 | -17.24 | -5.91 | -3.31 | |
9.94 | 2.17 | 17.78 | 9.53 | 6.41 | 0.69 | |
Net Cash Flow | 3.18 | -3.07 | 2.46 | -2.43 | -0.13 | 0.06 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 |
Inventory Days | ||||||
Days Payable | ||||||
Cash Conversion Cycle | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 |
Working Capital Days | 260.76 | 309.52 | 245.32 | 125.03 | 468.30 | 235.45 |
ROCE % | 8.35% | 5.21% | 3.77% | -5.82% | -4.16% |
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 14.11.2024
14 Nov - Board approved unaudited financial results for H1 2024.
- Unaudited Results For 30.09.2024 14 Nov
-
Board Meeting Intimation for Approval Of Un-Audited Financial Statements Of 30.09.2024 And Conversion Of Unsecured Loans Into Equity Shares
11 Nov - Board meeting on November 14 to discuss financial results.
-
Reply To Clarification On Price Movement Sought By BSE
7 Nov - Company clarifies price movement is market driven.
-
Clarification sought from Vanta Bioscience Ltd
6 Nov - Exchange has sought clarification from Vanta Bioscience Ltd on November 6, 2024 with reference to significant movement in price, in order to ensure that investors …
Business Overview:[1]
The company is a preclinical contract research organization, offering preclinical safety assessment services for clientele from the Pharmaceutical, Medical Devices, Nutraceuticals, Feed additives, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, the company also provides risk assessment services for evaluating the safety of Active Pharmaceutical Ingredients (API), excipients, extractable and leachable including pharmaceutical impurities resulting due to manufacturing process or degradation
of the product. VBS also provides expert services for the determination of health-based exposure limits e.g. permitted daily exposure or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.
Services Offered:
a) Toxicology[2]
b) Agro-chemical and Chemical Safety[3]
c) Bio Compatibility Studies[4]
d) Diet Formulation[5]
e) Batch Release Test[6]
f) Medical Devices[7]
g) Food Additives[8]
h) Cosmetics[9]